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Abstract
Repeated isolation of multidrug-resistant Acinetobacter baumannii (MDRAB) from respiratory secretions poses a great challenge for infec-
tion control. We conducted a retrospective case–control study to evaluate the efﬁcacy and adverse effect of inhaled colistin methane-
sulfonate (CMS) in the eradication of MDRAB from the respiratory tract. Patients who were admitted to Taipei Veterans General
Hospital between February 2009 and June 2010, had at least two sets of monomicrobial culture of MDRAB from respiratory secretions,
and remained in hospital for at least 14 days after the ﬁrst isolation of MDRAB (index day) were included. Patients who received intra-
venous CMS were excluded. Patients who received CMS inhalation for ‡3 days were selected as cases whereas the controls were
matched for age and Acute Physiology and Chronic Health Evaluation II score. Thirty-nine cases and controls were identiﬁed. The dura-
tion of CMS inhalation was 10.9 ± 3.6 days. The use of inhaled CMS was the only independent factor associated with the eradication of
MDRAB within 14 days after the index day (OR 266.33; 95% CI 11.26–6302.18, p <0.001), and shortened the duration of MDRAB
recovery from the respiratory tract by 13.3 ± 1.45 days. The adverse effects were similar for both groups. The increase of colistin mini-
mal inhibitory concentrations in the last isolate compared with the index isolate from the same patient did not differ between the two
groups. In conclusion, our study demonstrated that inhaled CMS enhanced the eradication of MDRAB from the respiratory tract with-
out signiﬁcant clinical adverse effect or impact on colistin resistance.
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Introduction
The three phenotypically undifferentiated Acinetobacter bau-
mannii complex (Abc) have become important nosocomial
pathogens [1]. Among them, A. baumannii is the most chal-
lenging for healthcare institutions globally because of its
multidrug resistance and proneness to cause outbreaks that
are difﬁcult to control [2]. The major infection caused by
A. baumannii is nosocomial pneumonia and A. baumannii can
also colonize respiratory tracts [3]. Acinetobacter baumannii
pneumonia is associated with a high mortality rate (36–
66.7%) and increases length of hospital stay [3–5]. Coloniza-
tion by A. baumannii is also associated with subsequent
A. baumannii infection and increases patient morbidity, mor-
tality and length of hospital stay [6–8]. In addition, strict and
costly infection control measures are always needed to con-
tain the outbreak [3,9]. As a result, the eradication of A. bau-
mannii may prevent the adverse clinical consequences and
decrease the vast expenditure of infection control [6,7].
Colistin is one of the limited drugs of choice for the treat-
ment of multidrug-resistant A. baumannii (MDRAB) with
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favourable clinical outcomes [10–12]. The colistin is modiﬁed
to a less toxic derivative, colistin methanesulfonate (CMS),
for intravenous use [13]. The CMS can also be delivered
through inhalation. The efﬁcacy of inhaled colistin in the
eradication of Pseudomonas aeruginosa has been reported
[14,15]. A few studies assessed the efﬁcacy of inhaled colistin
in addition to the concomitant intravenous use of different
antibiotics on the outcome of patients with pneumonia
caused by gram-negative bacilli [16–18]. These studies also
assessed the efﬁcacy of inhaled colistin on bacterial eradica-
tion, but the results were controversial [16,19]. Although
the major causative pathogens in these studies were Abc,
other gram-negative bacilli were also included [11,12,16–19].
The impact of therapy might vary among different pathogens
[1]. Moreover, Abc comprises three different species that
are different in terms of their antibiotic (including colistin)
susceptibility patterns [20,21] and possibly their pathogenicity
[1]. The heterogenicity of the pathogens might complicate
the interpretation of the results.
In this study, we conducted a case–control study to evaluate
whether in patients with or without concomitant intravenous
antibiotic therapy, the addition of inhaled CMS can enhance
the eradication of MDRAB from the respiratory tract.
Materials and Methods
Patient population
Taipei Veterans General Hospital is a 2900-bed tertiary cen-
tre in Taiwan. According to the guideline for infection con-
trol in our hospital, patients with MDRAbc cultured from
respiratory secretions received isolation and strict contact
precaution measures until three subsequent cultures from
respiratory secretions, which were performed every 3–
5 days, revealed a negative result for MDRAbc. During the
isolation, patients might receive inhaled CMS for the eradica-
tion of the MDRAbc according to the individual decision of
the physicians in charge. The dosage of inhaled CMS was
2 million international units (IU) (= 160 mg CMS) twice per
day, regardless of the patients’ renal function. The CMS was
reconstructed in 5–7 mL sterile normal saline and delivered
via a jet nebulizer with an oxygen ﬂow of 8 L/min in patients
without ventilator support. For patients with ventilator sup-
port, the inhaled CMS was delivered by means of the T-bird
AVS (Bird Products, Palm Springs, CA, USA). The extra cost
of the isolation room per patient in Taipei Veterans General
Hospital was about US$ 120 (double room without room-
mate) or US$ 180 (single room) per day.
This retrospective matched case–control study (ratio
1 : 1) assessed all adult patients (aged ‡18 years) who were
admitted from February 2009 to June 2010 and with at least
two sets of culture from respiratory secretions that showed
the monomicrobial growth of MDRAB. The day when the
ﬁrst MDRAB was isolated was deﬁned as the index day, and
the ﬁrst isolate was deﬁned as the index isolate. Patients
were excluded if they died or left hospital within 14 days
after the index day or their respiratory secretion could not
be collected regularly because the outcome of interest could
not be assessed. Patients were selected as case patients
when they had received inhaled CMS for ‡3 days after the
index day. Control patients were those who did not receive
inhaled CMS and were selected based on the following
matching criteria: age (±5 years), Acute Physiology and
Chronic Health Evaluation (APACHE) II score (±4 points)
[19]. Patients included in the study could have received con-
comitant intravenous antibiotics except CMS, as use of intra-
venous CMS might complicate the interpretation of results.
In selecting the control patients, the investigators did not
know the outcomes. This study was approved by the Institu-
tional Review Board of Taipei Veterans General Hospital
(2011-04-026IC).
Data collection and deﬁnition
Clinical data were retrospectively collected by reviewing the
medical records. Multidrug resistance was deﬁned as isolates
non-susceptible to all of the following antibiotics, including
carbapenems, anti-pseudomonas cephalosporins, anti-
pseudomonas penicillins, ﬂuoroquinolones, aminoglycosides,
tetracycline and trimethoprim/sulfamethoxazole. The MDRAB
could be either susceptible to colistin, tigecycline or sulbactam.
Pneumonia was diagnosed as previously described [22].
Early eradication was deﬁned if at least two consecutive
cultures from the respiratory secretions revealed no growth
of MDRAB and no MDRAB was recovered from subsequent
cultures, which were performed every 3–5 days until 14 days
after the index day. For patients with early eradication,
recurrence/recolonization was deﬁned as the recovery of
MDRAB 14 days after the index day. For patients without
early eradication, if the MDRAB continued to be isolated till
the end of the follow up or the 28th day after the index day,
the persistent isolation of MDRAB was considered.
Adverse effects were recorded. Haemodynamic instability
was considered when inotropic agents were mandated, and
bronchospasm when a bronchodilator therapy was needed.
Nephrotoxicity was deﬁned as an increase in baseline
creatinine of ‡44.2 lM for patients with normal renal func-
tion, ‡20% increase for those with previous renal dysfunc-
tion, or a decline in renal function that required renal
replacement therapy. If the patients underwent pre-existing
renal replacement therapy or the use of a mechanical
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ventilator on the index day, they were excluded from the
evaluation of nephrotoxicity and adverse respiratory effect,
respectively.
Microbiological studies
The Abc was phenotypically identiﬁed using the API ID
32GN system (bioMe´rieux, Marcy l’Etoile, France) and then
identiﬁed to the genomic species using a multiplex-PCR
method [23]. The antimicrobial susceptibilities were per-
formed by disk diffusion tests. The MICs of colistin were
determined by an agar dilution test using colistin sulfate
(Sigma Aldrich, St Louis, MO, USA) [24]. The genetic rela-
tionship of the isolates was determined by pulsed-ﬁeld gel
electrophoresis, as previously described [25].
Statistical analysis
A univariate analysis was performed using a Student’s t-test/
Mann–Whitney U-test, or Fisher’s exact tests/Pearson chi-
square test, as appropriate. A multivariate analysis was per-
formed to assess the relationship between the predictor
variables and the outcomes of interest. All analyses were
performed using the STATISTICAL PACKAGE FOR THE SOCIAL
SCIENCES version 18.0 (SPSS, Chicago, IL, USA). A value of
p <0.05 was considered to be statistically signiﬁcant.
Results
During the study period, 1020 patients experienced
MDRAbc growth from respiratory secretions. Among 291
patients who had monomicrobial growth of MDRAbc and
had stayed in hospital for ‡14 days, 49 patients had received
CMS inhalation therapy for ‡3 days but not concomitant
intravenous CMS. Ten patients were excluded because the
bacteria were identiﬁed as other Acinetobacter species.
Finally, 39 patients were available as cases and 39 corre-
sponding controls were identiﬁed. The duration of the
inhaled CMS therapy was 10.9 ± 3.6 days. The demographic
data, underlying diseases and invasive procedures are listed
in Tables 1 and 2 (Supplementary data). A comparable por-
tion of patients in case and control groups (10/39 vs 8/39,
p <0.591) had received intravenous antibiotic therapy (either
for MDRAB pneumonia or other infections) that had an in vi-
tro activity against the MDRAB.
During the subsequent cultures, the last cultures positive
for MDRAB in the case group were at day 8.2 ± 6.4 after
the index day, but were at day 21.5 ± 4.5 (p <0.001) in the
control group. The extra expenditure to cover the isolation
room fees because of the prolonged isolation of the control
group was around US$ 1596 ± 174 to 2394 ± 261 per
patient. In contrast, the extra expenditure for the inhaled
CMS in the case group was US$ 115 ± 38 per patient. The
early eradication rate within 14 days after the index day of
MDRAB isolation from respiratory secretions (Table 3) was
higher in the case group than in the control group (84.6% vs
10.3%; p <0.001). In the subgroup analysis of patients with
colonization or pneumonia, the early eradication rates were
both higher in the case group than control group [95.7%
(22/23) vs 7.4% (2/27), p <0.001; 68.8% (11/16) vs 16.7% (2/
12), p 0.009]. Among the cases with early eradication, 78.8%
continued to be free of respiratory colonization and/or infec-
tion from MDRAB. In patients without early eradication, the
percentage of patients who experienced persistent isolation
of MDRAB in the two groups was similar (50% (3/6) vs
57.1% (20/35)); p >0.99].
To investigate whether the inhaled CMS was an indepen-
dent factor associated with the early eradication of MDRAB,
other factors associated with the early eradication (Table 4)
were entered into the multivariate analysis. Only the use of
inhaled CMS was the independent factor associated with the
early eradication of MDRAB (OR 266.33; 95% CI 11.26–
6302.18, p <0.001).
The incidence of haemodynamic instability, need for intu-
bation, or nephrotoxicity did not differ between the case
and control groups (Table 3). No bronchospasm was
observed in either group. The 28-day and in-hospital mortal-
ity rate did not differ between the two groups.
The index isolates in the case and control groups
belonged to 28 and 23 different pulsotypes, respectively
(data not shown). No speciﬁc pulsotype was found. All of
the index isolates were resistant to imipenem, ceftazidime,
cefoperazone, cefepime, piperacillin/tazobactam, ciproﬂoxa-
cin, levoﬂoxacin, gentamicin, tetracycline and trimethoprim/
sulfamethoxazole. Seventy-ﬁve isolates (96.2%) were also
resistant to sulbactam. Seventy index isolates (89.7%)
showed a susceptibility to colistin, with the MIC ranging
from 0.5 to 2 mg/L. Eight isolates were resistant to colistin
(with MIC of 4 mg/L (seven isolates) and 8 mg/L (one iso-
late)), among which six were in the case group and two in
the control group (15.4% vs 5.1%, p 0.135). Five of the six
case patients harbouring the colistin-resistant MDRAB had
their isolates eradicated within 14 days whereas neither of
the two control patients did. Overall, the early eradication
rate within 14 days between patients with colistin-resistant
or colistin-susceptible isolates was similar (5/8 (62.5%) vs 32/
70 (45.7%), p 0.368). The early eradication of colistin-resis-
tant and colistin-susceptible isolates did not differ in the case
group (5/6 (83.3%) vs 28/33 (84.8%), p 0.925).
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The last positive MDRAB isolates from 28 case patients
and 30 control patients were available. Sixteen (57.1%) last
isolates in the case group belonged to the same pulsotype as
their index isolates, whereas in the control group 13 (43.3%)
isolates did (Supplementary data). The proportion of last iso-
lates with increased colistin MIC compared with the index
isolates from the same patients did not differ signiﬁcantly
between the two groups (Table 3). Two follow-up isolates
from each group had colistin MIC at resistant levels. In the
case group, both were eradicated within 14 days. In the con-
trol group, one was eradicated within 14 days and the other
persisted at day 28 after the index day.
Discussion
To the best of our knowledge, this was the ﬁrst matched
case–control study focusing on the efﬁcacy of inhaled CMS
in the eradication of respiratory MDRAB, which was identi-
ﬁed to the genomic species level. We found that inhaled
CMS enhanced the eradication of MDRAB from the respira-
tory tract and was not associated with signiﬁcant adverse
effects or the emergence of colistin resistance.
The inhaled CMS shortened the duration of MDRAB
recovery from the respiratory tract by 13.3 ± 1.45 days.
Fourteen days after the index day, a signiﬁcant number of
case patients had their MDRAB eradicated. Although there
were some differences in the background between the two





(n = 39) p
Age, mean years ± SD 78 ± 13.1 81.3 ± 10.2 0.227
Sex, male 34 (87.2) 26 (66.7) 0.032
APACHE II score at
index dayb, mean ± SD
20.0 ± 6.2 21.1 ± 4.5 0.349
APACHE II score at day 14
after index day, mean ± SD
20.4 ± 6.4 20.5 ± 4.9 0.943
Colonization 23 (59.0) 27 (69.2) 0.345
Pneumonia 16 (41.0) 12 (30.8) 0.345
Stay in intensive care unit 28 (71.8) 33 (84.6) 0.170
Hospitalization day prior to
index day, mean days ± SD
62.8 ± 135.9 43.5 ± 130.0 0.523
aData are presented as number (%) of patients, unless stated otherwise.
bIndex day was deﬁned as the ﬁrst day when the multi-drug resistant Acinetobac-
ter baumannii was isolated from respiratory secretion.
SD, standard deviation; APACHE, acute physiology and chronic health evalua-
tion.






(n = 39) p
Predisposing factorsb
Chronic renal disease 23 (59.0) 19 (48.7) 0.364
Bed-ridden 22 (56.4) 21 (53.8) 0.820
Hypertension 16 (41.0) 18 (46.2) 0.648
Diabetes mellitus 15 (38.5) 11 (28.2) 0.337
Chronic lung diseases 14 (35.9) 16 (41.0) 0.642
Cerebrovascular diseases 13 (33.3) 11 (28.2) 0.624
Congestive heart failure 12 (30.8) 11 (28.2) 0.804
Coronary artery disease 12 (30.8) 6 (15.4) 0.107
Steroid use 11 (28.2) 19 (48.7) 0.063
Solid organ tumor 9 (23.1) 6 (15.4) 0.389
Major operation 6 (15.4) 2 (5.1) 0.135
Collagen disease 4 (10.3) 3 (7.7) 0.692
Renal replacement therapy 3 (7.7) 3 (7.7) >0.99
Liver cirrhosis 3 (7.7) 1 (2.6) 0.305
Chemotherapy 2 (5.1) 1 (2.6) 0.556
PAOD 2 (5.1) 0 (0) 0.152
Trauma 1 (2.6) 2 (5.1) 0.556
Invasive procedures use
Nasogastric tube 36 (92.3) 38 (97.4) 0.305
Foley catheter 23 (59.0) 30 (76.9) 0.089
Mechanical ventilation 15 (38.5) 23 (59.0) 0.070
Duration of mechanical ventilation
prior to index day, mean days ± SD
5.7 ± 6.7 7.9 ± 6.6 0.137
Central venous catheterization 13 (33.3) 16 (41.0) 0.482
Tracheostomy 10 (25.6) 10 (25.6) >0.99
Arterial catheterization 5 (12.8) 11 (28.2) 0.092
Abdominal drainage 1 (2.6) 0 (0) 0.314
Total parental nutrition 0 (0) 2 (5.1) 0.152
Previous intravenous antibiotic use 38 (97.4) 31(79.5) 0.013
Carbapenems 18 (46.2) 7 (17.9) 0.008
Sulbactam or ampicillin/sulbactam 9 (23.1) 5 (12.8) 0.238
Tigecycline 9 (23.1) 2 (5.1) 0.023
Anti-pseudomonas beta-lactams 24 (61.5) 23 (59.0) 0.817
Ciproﬂoxacin or levoﬂoxacin 9 (23.1) 10 (25.6) 0.792
Aminoglycosides 2 (5.1) 2 (5.1) >0.99
Concomitant intravenous antibiotic use 32 (82.1) 31 (79.5) 0.774
Carbapenems 18 (46.2) 6 (15.4) 0.003
Sulbactam or ampicillin/sulbactam 11 (28.2) 12 (30.8) 0.804
Tigecycline 10 (25.6) 8 (20.5) 0.591
Anti-pseudomonas beta-lactams 9 (23.1) 16 (41.0) 0.089
Ciproﬂoxacin or levoﬂoxacin 2 (5.1) 9 (23.1) 0.023
Aztreonam 1 (2.6) 0 (0) 0.314
Aminoglycosides 1 (2.6) 0 (0) 0.314
aData are presented as number (%) of patients, unless stated otherwise.
bPredisposing factors with a prevalence of <5% in both groups was not shown.
PAOD, peripheral arterial occlusive disease; SD, standard deviation.
TABLE 3. Outcomes and adverse effects of patients in the





(n = 39) p
Microbiological outcome
Eradication within 14 days 33 (84.6) 4 (10.3) <0.001
Recurrence/recolonization 7/33 (21.2) 0/4 (0) 0.570
Persistent isolation 3/6 (50) 20/35 (57.1) >0.99
Change of colistin MIC between
the last isolate and the index
isolate from the same patient
1–2-fold increase 8/28 (28.6)b 4/30 (13.3)b 0.152
Cumulative adverse effects at
day 14 after index day
Hemodynamic instability 4 (10.3) 4 (10.3) >0.99
Acute renal failure 6/36 (16.7) 7/36 (19.4) 0.759
Need for renal replacement therapy 2/36 (5.6) 2/36 (5.6) >0.99
Need for intubation 4/24 (16.7) 2/16 (12.5) 0.718
Cumulative adverse effects at
day 28 after index day
Hemodynamic instability 7 (17.9) 5 (12.8) 0.530
Acute renal failure 11/36 (30.6) 9/36 (25.0) 0.599
Need for renal replacement therapy 3/36 (8.3) 2/36 (5.6) 0.643
Need for intubation 5/24 (20.8) 3/16 (18.8) 0.872
Clinical outcome
28-day mortality 5 (12.8) 4 (10.3) 0.723
In-hospital mortality 16 (41.0) 13 (33.3) 0.482
aData are presented as number (%) of patients, unless stated otherwise.
bNot all of the last isolates were available from the case and control groups.
MIC, minimal inhibitory concentration.
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groups, the multivariate analysis identiﬁed that inhaled CMS
was still the only independent factor associated with early
eradication. In 78.8% of the case patients who had the early
eradication of MDRAB, the culture remained negative after
cessation of the inhaled CMS, indicating that the negative cul-
ture that resulted during CMS inhalation was not merely the
result of the carryover effect of CMS.
The high microbiological eradication rate in our study
was consistent with previous cohort studies and one com-
parative study [11,12,16–18]. However, a recent compara-
tive study using 1 million IU twice daily of colistin showed
no microbiological beneﬁt [19]. The high dose of inhaled
CMS might explain part of the high eradication rate in our
study. A peak concentration approaching 40 mg/L has been
found after inhalation of a single dose of 2 million IU colis-
tin [14]. The eradication of index isolates that had colistin
MIC at resistant levels might also be due to the high con-
centration in the airway. The best delivery method for
inhaled CMS has not been conﬁrmed. The results of our
study indicated that the current preparation and delivery
method might be adequate for the eradication of the respi-
ratory MDRAB.
One of the beneﬁts of the early eradication of MDRAB
from the respiratory tract by inhaled CMS was decreased
hospital cost, at least those resulting from the isolation ward
fee. In our hospital, this meant a saving of at least US$
1596 ± 174 to 2394 ± 261 per patient. This certainly under-
estimated the costs, especially those resulting from man-
power, which were hard to estimate, and the disposable
consumables used in the contact precautions. Nevertheless,
the beneﬁt of inhaled CMS in other countries, including
those with lower incidences of MDRAB colonization and dif-
ferent infection control policies, cannot be extrapolated. In
addition, it remains to be determined whether there is any
other beneﬁt resulting from the eradication of MDRAB,
including the prevention of subsequent infection and the con-
tainment of an outbreak.
There was no associated bronchospasm, which would
mandate the use of a bronchodilator, in our study. The
incidence of serious respiratory events (need for intubation)
and nephrotoxicity was similar between the two groups,
which was in agreement with most previous clinical studies
[11,16,17,19]. The systemic adverse effects of colistin were
avoided because of the low systemic concentration of colis-
tin after inhalation [14].
Unexpectedly, the isolates recovered from the subsequent
culture revealed different pulsotypes compared with the
index isolates in half of the patients in both groups. The
results indicated the complexity of A. baumannii colonization
that could only be detected with molecular epidemiology
tools. The change of colistin MIC between the two groups
did not differ signiﬁcantly. Two colistin-resistant isolates in
the case group emerged but both were eradicated. The high
concentration of colistin over MIC of the isolate might be
responsible for the rarity of the emergence of resistance and
the eradication of the resistant isolates. The other reason
for the scarcity of emergence of colistin resistance in A. bau-
mannii, especially in vivo, is that colistin resistance in A. bau-
mannii may be associated with a loss of biological ﬁtness and
the intrinsic instability of the resistance [26–28].
In our study consisting mostly of colonized patients (59%
in the case group and 69.2% in the control group), we did
not assess the efﬁcacy of inhaled CMS on patients’ clinical
outcomes, including success in infection. Moreover, after
excluding patients with early mortality (within 14 days), we
only assessed 28-day and in-hospital mortality in our study.
Not surprisingly, the inhaled CMS did not reduce the mortal-
ity of patients mostly with colonization.
In conclusion, our study demonstrated that inhaled CMS
offered a microbiological beneﬁt in patients with MDRAB







(n = 41) p
Multivariate
OR (95% CI) p
Age, mean years ± SD 76.3 ± 14.0 82.7 ± 8.4 0.018 0.465
Chronic lung disease 9 (24.3) 21 (51.2) 0.015 0.090
Steroid use 10 (27.0) 20 (48.8) 0.049 0.925
Use of arterial catheterization 4 (10.8) 12 (29.3) 0.044 0.805
Use of nasogastric tube 33 (89.2) 41 (100) 0.031 >0.99
Duration of mechanical
ventilator use prior to index
day, mean days ± SD
4.84 ± 6.25 8.56 ± 6.65 0.013 0.114
Previous use of carbapenem 17 (45.9) 8 (19.5) 0.012 0.612
Previous use of tigecycline 9 (24.3) 2 (4.9) 0.014 0.971
Concomitant use of
ciproﬂoxacin or levoﬂoxacin
0 (0) 11 (26.8) <0.001 >0.99
CMS inhalation 33 (89.2) 6 (14.6) <0.001 266.33 (11.26–6302.18) <0.001
aData are presented as number (%) of patients, unless stated otherwise.
OR, odds ratio; CI, conﬁdence interval; SD, standard deviation; CMS, colistin methanesulfonate.
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from the respiratory tract and decreased need for
expenditure on isolation. No signiﬁcant clinical adverse effect
or emergence of resistance was associated with CMS
inhalation.
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